 "Venus Remedies eyes Rs 1000 crore turnover by FY18")
"We are looking at double digit growth and target turnover of Rs 1,000 crore following several new drug launches and increased marketing efforts. The company has registered a turnover of Rs 525 crore in FY14," Venus Remedies Chairman and Managing Director Pawan Chaudhary told PTI here.
The company has invested around Rs 500 crore in R&D over the last 10 years and received 100 plus patents, 70 trademarks, 9 copyrights and 120 research publications in peer reviewed journals for its R&D based products across the globe, Chaudhary said adding the investment in R&D will continue.
More From This Section
The company has 25 innovative products in pipeline and commercialised 15 products in domestic and international markets, he said, adding Venus has presence in 40 markets globally.
Following the GMP certification by European and other regulated markets for its manufacturing plants, the company has been able to make international tie-ups for its research products with some of the best pharmaceutical companies of the world, he said said.
"The company is negotiating with overseas partners for out licensing some block buster products. The company is looking at partners who can invest in research and marketing," Chaudhary said.
In the past one year alone, Venus has extended its footprint across the globe by way of marketing authorisations, strategic tie-ups and patent grants. Having a presence in 60 countries, Venus has received more than 65 marketing authorisations from regulated markets across the globe.
The company has already signed an MoU with South African pharmaceutical firm Austell Laboratories to exclusively out licence its flagship antibiotic research product, Elores, in South Africa. Earlier, the product was out licensed to Goodwill Pharma, a South Korean company.